Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK

Blandine French , James Davies , Chris Williams , Amanda Kirby

Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) : 1004163

PDF (3945KB)
Exploration of Neuroprotective Therapy ›› 2026, Vol. 6 ›› Issue (1) :1004163 DOI: 10.37349/ent.2026.1004163
Original Article
research-article
Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK
Author information +
History +
PDF (3945KB)

Abstract

Aim: Attention deficit hyperactivity disorder (ADHD) is a common condition impacting approximately 5% of children and 3–4% of adults in the United Kingdom (UK). While it cannot be cured, treatment has been shown to positively impact the difficulties associated with ADHD. However, ADHD is widely underdiagnosed and undertreated in the UK. This paper reports the results of a model developed to estimate pharmacological treatment rates by area across National Health Service (NHS) integrated care systems (ICSs) in England, health boards in Scotland and Wales, and health & social care trusts (HSCTs) in Northern Ireland. Methods: The model used the UK general population and ADHD prevalence data to estimate the number of patients with ADHD in each area. Prescription data for medicines licensed for the treatment of ADHD were then used to estimate the number of patients who are untreated and treated, and the percentage treatment rates by area. The analysis was descriptive, focusing on quantifying geographic variation in treatment rates. Results: Nationally, the estimated proportions of children and young people (CYP; 5–17 years) and adults (18–65 years) treated were 26.6% and 15.6%, respectively, of the expected ADHD populations. Treatment rates by ICS or health board in England, Scotland, and Wales ranged from 11.7% to 60.6% for the CYP population and 8.6% to 24.8% for the adult population (data for Northern Ireland were not available by age group). Overall treatment rates (ages 5–65 years) in Northern Ireland ranged from 6.7% in the lowest-ranking HSCT to 31.1% in the highest-ranking HSCT. Conclusions: In the UK, there is currently a high degree of geographic variation across all NHS systems and a generally low level of treatment of ADHD, especially in adults. Up to a 4.6-fold difference in pharmacological treatment rates was observed between NHS service provider areas.

Keywords

ADHD / treatment / treatment rates / variation model / healthcare services

Cite this article

Download citation ▾
Blandine French, James Davies, Chris Williams, Amanda Kirby. Geographical differences in attention deficit hyperactivity disorder treatment rates across the UK. Exploration of Neuroprotective Therapy, 2026, 6 (1) : 1004163 DOI:10.37349/ent.2026.1004163

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry. 2007; 20: 386-92.

[2]

Sayal K, Prasad V, Daley D, Ford T, Coghill D. ADHD in children and young people: prevalence, care pathways, and service provision. Lancet Psychiatry. 2018; 5: 175-86.

[3]

Song P, Zha M, Yang Q, Zhang Y, Li X, Rudan I ; on behalf of the Global Health Epidemiology Reference Group (GHERG). The prevalence of adult attention-deficit hyperactivity disorder: A global systematic review and meta-analysis. J Glob Health. 2021; 11: 04009.

[4]

CKS via NICE is only available to eligible users within the UK [Internet]. NICE; c2026 [cited 2026 Jun 9]. Available from: https://cks.nice.org.uk/topics/attention-deficit-hyperactivity-disorder/background-information/prevalence/

[5]

Ginsberg Y, Quintero J, Anand E, Casillas M, Upadhyaya HP. Underdiagnosis of attention-deficit/hyperactivity disorder in adult patients: A review of the literature. Prim Care Companion J Clin Psychiatry. 2014; 16.

[6]

Danckaerts M, Sonuga-Barke EJS, Banaschewski T, Buitelaar J, Döpfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010; 19: 83-105.

[7]

French B, Nalbant G, Wright H, Sayal K, Daley D, Groom MJ, et al. The impacts associated with having ADHD: an umbrella review. Front Psychiatry. 2024; 15: 1343314.

[8]

Wright N, Moldavsky M, Schneider J, Chakrabarti I, Coates J, Daley D, et al. Practitioner Review: Pathways to care for ADHD - a systematic review of barriers and facilitators. J Child Psychol Psychiatry. 2015; 56: 598-617.

[9]

French B, Sayal K, Daley D. Barriers and facilitators to understanding of ADHD in primary care: a mixed-method systematic review. Eur Child Adolesc Psychiatry. 2019; 28: 1037-64.

[10]

French B, Daley D, Groom M, Cassidy S. Risks Associated With Undiagnosed ADHD and/or Autism: A Mixed-Method Systematic Review. J Atten Disord. 2023; 27: 1393-410.

[11]

DuPaul GJ, Weyandt LL, Janusis GM. ADHD in the Classroom: Effective Intervention Strategies. Theory Pract. 2011; 50: 35-42.

[12]

Daughton JM, Kratochvil CJ. Review of ADHD Pharmacotherapies: Advantages, Disadvantages, and Clinical Pearls. J Am Acad Child Adolesc Psychiatry. 2009; 48: 240-8.

[13]

Craig SG, Davies G, Schibuk L, Weiss MD, Hechtman L. Long-Term Effects of Stimulant Treatment for ADHD: What Can We Tell Our Patients? Curr Dev Disord Rep. 2015; 2: 1-9.

[14]

Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res. 2020; 123: 21-30.

[15]

Report of the independent ADHD Taskforce [Internet]. [cited 2026 Jun 12]. Available from: https://www.england.nhs.uk/publication/report-of-the-independent-adhd-taskforce/

[16]

NHS to launch cross-sector ADHD taskforce to boost care for patients in England [Internet]. [cited 2026 Jun 12]. Available from: https://www.england.nhs.uk/2024/03/nhs-to-launch-cross-sector-adhd-taskforce-to-boost-care-for-patients-in-england/

[17]

Vibert S. Your Attention Please: The Social and Economic Impact of ADHD [Internet]. Demos. Some rights reserved; c2018 [cited 2026 Jun 12]. Available from: https://demos.co.uk/wp-content/uploads/2018/12/Your-Attention-Please-the-social-and-economic-impact-of-ADHD-.pdf

[18]

Chhibber A, Watanabe AH, Chaisai C, Veettil SK, Chaiyakunapruk N. Global Economic Burden of Attention-Deficit/Hyperactivity Disorder: A Systematic Review. PharmacoEconomics. 2021; 39: 399-420.

[19]

Daley D, Jacobsen RH, Lange AM, Sørensen A, Walldorf J. The economic burden of adult attention deficit hyperactivity disorder: A sibling comparison cost analysis. Eur Psychiatry. 2019; 61: 41-8.

[20]

Clark DM. Implementing NICE guidelines for the psychological treatment of depression and anxiety disorders: The IAPT experience. Int Rev Psychiatry. 2011; 23: 318-27.

[21]

Lamberg L. ADHD often undiagnosed in adults: appropriate treatment may benefit work, family, social life. JAMA J Am Med Assoc. 2003; 290: 1565-7.

[22]

Waite R, Ramsay JR. Adults with ADHD: Who Are We Missing? Issues Ment Health Nurs. 2010; 31: 670-8.

[23]

Madsen KB, Ravn MH, Arnfred J, Olsen J, Rask CU, Obel C. Characteristics of undiagnosed children with parent-reported ADHD behaviour. Eur Child Adolesc Psychiatry. 2018; 27: 149-58.

[24]

McKechnie DGJ, O’Nions E, Dunsmuir S, Petersen I. Attention-deficit hyperactivity disorder diagnoses and prescriptions in UK primary care, 2000-2018: population-based cohort study. BJPsych Open. 2023; 9: e121.

[25]

Health geographies population estimates (Accredited official statistics) [Internet]. [cited 2025 Feb 3]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/datasets/clinicalcommissioninggroupmidyearpopulationestimates

[26]

Health Board (2019) Population Estimates [Internet]. [cited 2025 Feb 3]. Available from: https://www.opendata.nhs.scot/dataset/population-estimates/resource/27a72cc8-d6d8-430c-8b4f-3109a9ceadb1

[27]

2022 Mid-Year Population Estimates for Small Geographical Areas within Northern Ireland [Internet]. NISRA; [cited 2025 Feb 3]. Available from: https://www.nisra.gov.uk/publications/2022-mid-year-population-estimates-small-geographical-areas

[28]

Chang Z, Lichtenstein P, Larsson H. The effects of childhood ADHD symptoms on early-onset substance use: a Swedish twin study. J Abnorm Child Psychol. 2012; 40: 425-35.

[29]

French B, Perez Vallejos E, Sayal K, Daley D. Awareness of ADHD in primary care: stakeholder perspectives. BMC Fam Pract. 2020; 21: 45.

[30]

Price A, Janssens A, Newlove-Delgado T, Eke H, Paul M, Sayal K, et al. Mapping UK mental health services for adults with attention-deficit/hyperactivity disorder: national survey with comparison of reporting between three stakeholder groups. BJPsych Open. 2020; 6: e76.

[31]

Smith MCF, Mukherjee RAS, Müller-Sedgwick U, Hank D, Carpenter P, Adamou M. UK adult ADHD services in crisis. BJPsych Bull. 2024; 48: 1-5.

[32]

Wright RJ, Howard EJ, Newbery N, Gleeson H. ‘Training gap’ - the present state of higher specialty training in adolescent and young adult health in medical specialties in the UK. Future Healthc J. 2017; 4: 80-95.

[33]

Biederman J, DiSalvo M, Fried R, Woodworth KY, Biederman I, Faraone SV. Quantifying the Protective Effects of Stimulants on Functional Outcomes in Attention-Deficit/Hyperactivity Disorder: A Focus on Number Needed to Treat Statistic and Sex Effects. J Adolesc Health. 2019; 65: 784-9.

[34]

Ramos-Quiroga JA, Richarte V, Soto I, Targhetta M, Ward J, Perulero N. The Prevalence and Treatment of ADHD in Spain: A Retrospective Cohort Analysis. J Atten Disord. 2023; 27: 273-82.

[35]

Update on ADHD Medication Shortage [Internet]. NHS Cheshire and Merseyside; [cited 2026 Jun 9]. Available from: https://www.cheshireandmerseyside.nhs.uk//your-health/prescribing/update-on-adhd-medication-shortage/

[36]

Statement on shortage of ADHD medication [Internet]. Royal College of Psychiatrists; c2026 [cited 2026 Jun 26]. Available from: https://www.rcpsych.ac.uk/news-and-features/latest-news/detail/2023/10/19/statement-on-shortage-of-adhd-medication

[37]

Choice [Internet]. [cited 2026 Jun 26]. Available from: https://www.england.nhs.uk/personalisedcare/choice/

[38]

Gudka R, Becker K, Ward J, Smith JR, Mughal F, Melendez-Torres GJ, et al. Primary care provision for young people with ADHD: a multi-perspective qualitative study. Br J Gen Pract. 2024; 74: e408-16.

PDF (3945KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉